Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Treatment For Type 1 Retinopathy of Prematurity
NCT04634578Phase 2Active, not recruiting
- Sponsor
- Jaeb Center for Health Research
- Start
- May 2022
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised trial of bevacizumab in retinopathy of prematurity (ROP) (2 arms), sponsored by Jaeb Center for Health Research. Primary endpoint: Treatment Success at 4 Weeks Post Injection. Started May 2022; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT04634578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634578.